Abram Damato, MD
Urology · Hartford, CTNPI 1922326628
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 217 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations.
Across 217 payments — averaging $25.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$733
- Johnson & Johnson$699
- Antares Pharma, Inc.$288
- AbbVie$249
- Merck$233
- Calyxo, Inc.$210
- plus $3K from 35 others
What the payments were for
- Food & beverage$5,43498%
- Education$1142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 31 | $733 |
| Johnson & Johnson | 27 | $699 |
| Antares Pharma, Inc. | 13 | $288 |
| AbbVie(2 entities) | 13 | $249 |
| Merck | 11 | $233 |
| Calyxo, Inc. | 4 | $210 |
| Agiliti Surgical, Inc. | 4 | $201 |
| Teleflex LLC | 10 | $201 |
| Pfizer | 10 | $200 |
| Tolmar, Inc. | 8 | $197 |
| C. R. Bard, Inc. & Subsidiaries | 4 | $195 |
| Axonics, Inc. | 5 | $192 |
| Ferring Pharmaceuticals Inc. | 9 | $176 |
| Bayer | 7 | $170 |
| Histosonics, Inc. | 1 | $154 |
| Boston Scientific | 1 | $142 |
| Progenics Pharmaceuticals, Inc. | 6 | $131 |
| Procept Biorobotics Corporation | 3 | $114 |
| Myovant Sciences Inc. | 5 | $108 |
| Urogen Pharma, Inc. | 3 | $75 |
| Coloplast | 3 | $67 |
| Astellas Pharma US Inc | 3 | $66 |
| Acerus Pharmaceuticals Corporation | 4 | $64 |
| Medtronic | 3 | $62 |
| Myriad Genetic Laboratories, Inc. | 3 | $60 |
| Urovant Sciences Inc | 3 | $55 |
| Accord Healthcare, Inc. | 3 | $53 |
| Immunitybio, Inc. | 2 | $49 |
| Halozyme Inc | 2 | $47 |
| Photocure Inc | 2 | $43 |
| Vertex | 2 | $41 |
| Amgen | 2 | $41 |
| Dentsply IH AB | 1 | $40 |
| Janssen Scientific Affairs, LLC | 1 | $37 |
| Endo Pharmaceuticals Inc. | 2 | $31 |
| Sanofi | 1 | $25 |
| Exact Sciences | 1 | $22 |
| Endo USA, Inc. | 1 | $22 |
| Tolmar Pharmaceuticals, Inc. | 1 | $22 |
| Olympus America Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,548 in reported general payments places this provider in the 70th percentile of 156 urology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 267 | $288,138 |
| OrgovyxRelugolix | 26 | $68,914 |
| MyrbetriqMirabegron | 41 | $36,062 |
| Tamsulosin Hcl | 642 | $7,167 |
| Tolterodine Tartrate ErTolterodine Tartrate | 98 | $6,878 |
| Tadalafil | 16 | $3,578 |
| Potassium Citrate ErPotassium Citrate | 17 | $2,414 |
| Methenamine Hippurate | 98 | $2,261 |
| Solifenacin Succinate | 28 | $1,212 |
| Oxybutynin Chloride ErOxybutynin Chloride | 43 | $1,154 |
| Finasteride | 86 | $873 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 15 | $518 |
| Bicalutamide | 19 | $339 |
| Doxycycline Hyclate | 14 | $289 |
| Celecoxib | 21 | $201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $733 | $357,052293 claims |
| Astellas Pharma US IncMyrbetriq | $66 | $36,06241 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 156 urology providers in Connecticut.
Other urology in Hartford
- Steven ShichmanHartford$28K
- Joseph WagnerHartford$21K
- Eric KatzHartford$14K
- Jared BieniekHartford$9K
- Shanta ShepherdHartford$8K
- Christine CumarasamyHartford$6K
- Guy TronoHartford$6K
- Peter BoscoHartford$3K
- Aaron TurnquistHartford$3K
- Daniel KellnerNew Haven$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.